Navigation Links
KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
Date:11/13/2008

ST. LOUIS, Nov. 13 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa; KVb) announced that it has filed with the U.S. Securities and Exchange Commission a Form 12b-25 notification that its Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 will be delayed.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures and markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its emerging branded drug subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expect", "aim"," believe", "projects", "anticipates", "commit", "intend", "estimate", "will", "should", "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, all statements pertaining to the Company's Form 10-Q for the second quarter of fiscal year 2009 with the Securitie
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...aunched a series of clinical trials in order to as...his approach involves the application of personali...s from the patient him or herself and designed to ...nd frequent malignant tumours. The new therapy is ...th the standard, first-line treatment involving su...
(Date:11/30/2009)...do knees, internal injuries, study finds, , ...re a middle-age weekend warrior who likes to hit t...ew study suggests that high levels of physical act...could lead to osteoarthritis. , The study found...ho showed no symptoms and had a healthy weight. Th...
(Date:11/30/2009)...giving catalog to help families make charitable gi... 30 In spite of the eco...y season willing to support charities in two ways,...wn wallets to support charities and nearly 40 perc...instead of buying them a gift, according to a new ...
(Date:11/30/2009)...ewswire-FirstCall/ -- Stryker Corporation (NYSE: ...acquire privately held Ascent Healthcare Solutions...emanufacturing of medical devices in the U.S. ,...acquire Ascent Healthcare Solutions for $525 milli...itioned on the expiration or termination of all ap...
(Date:11/30/2009)...k up , , MONDAY, Nov. 30 (HealthDay News...e U.S. Congress differ in a number of ways but ach...mber of uninsured Americans. , Legislation appr...month would expand coverage to 96 percent of Ameri... to expand coverage to 94 percent of Americans. ,...
Breaking Medicine News(10 mins):Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 2Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 3Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 2Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 3Health News:Health Reform: What's in It for You? 2Health News:Health Reform: What's in It for You? 3
...enefits of Frameless Delivery and Fractionation De... Preservation , , SUNNYVALE, Calif., May 5 Accur... in the field of radiosurgery, announced today tha...ion of Neurological Surgeons (AANS) Annual Meeting...
...nline and Phone Based Survey Encourages Nurses to ...areers , , , PORTLAND, Ore., May 5 Vigilan, the...brates National Nurse Week May 6-12, 2009 by liste...ementia care. Vigilan is offering an online and p...
...ONDON, May 5 Initiatives taken by European govern...ion surveillance systems have aimed at improving e...r, the lack of basic level automation is proving t...ts across Europe to install infection surveillance...
...ADISON HEIGHTS, Mich., May 5 InfuSystem Holdings... the leading provider of ambulatory infusion pumps... financial results and provided a business update ...e first quarter of 2009, despite a nationwide shor...
...irst Diagnostic Test for Identifying E. coli, K. p... Blood Cultures , , PNA FISH Provides Critical Re... to Help Clinicians Improve Care and Outcomes for ...0(k) clearance for EK/ P. aeruginosa PNA FISH(R) ...
... , , REDWOOD CITY, Calif., May 5 Ingenuity Syste...for life science researchers, today announced a mu...plans to expand the utilization of IPA in its rese... researchers plan to leverage the powerful analysi...
Other Medicine News:Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 2Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 3Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 4Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 5Health News:Vigilan Honors National Nurse Week in Assisted Living, Independent Living and Dementia Care 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 3Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 2Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 3Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 4Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 5Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 6Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 7Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 2Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 3Health News:Ingenuity Systems Announces Multi-Year Deal With AstraZeneca 2Health News:Ingenuity Systems Announces Multi-Year Deal With AstraZeneca 3
(Date:11/30/2009)..., WALTHAM, Mass., Nov. 30 Decis... and advisory firms focusing on pharmaceutical and... virus drug market in Russia will grow nine percen...hing $327 million by 2013. This growth will be dri...lthcare and increased use of more-expensive therap...
(Date:11/30/2009)... , INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall...as approved Cymbalta® (duloxetine HCl) for th...order (GAD) in adults, Eli Lilly and Company (NYSE...d anxiety disorder can be a chronic illness, it is...treatment option that is effective in both the acu...
(Date:11/30/2009)..., BRIDGEWATER, N.J., Nov. 30 /PRNewswire-FirstCall...ng of an exclusive licensing agreement with Intell...for the emergency treatment of allergic reactions ... ,, "We are pleased to have this opportunity to...lions of people who are at risk of this life-threa...
Breaking Medicine Technology:Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 1China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 2China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 4China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 5China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 6China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 7China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 8China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 9China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 10China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 11China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 12China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 13Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 1Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 1MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 3MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 4
...YORK, May 16 Pulmo BioTech Inc. (OTC,Bulletin Boa...ogy and,purpose of its Phase I Human Trials with i...diagnosis of Pulmonary Embolism and Pulmonary,Hype...lmo BioTech subsidiary,PulmoScience Inc., and the ... PulmoBind for Molecular Imaging of the Pulmonary ...
...GEWATER, N.J., May 16 Data from three studies,eva...emoglobin (Hb) levels,and the rate of blood transf...ions on reimbursement for erythropoiesis-stimulati...n,s blood supply, will be presented at the,America...ng later this,month. The meeting will take place i...
Other Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6
Revo Rotator Cuff Repair System
BioROC EZ Fasteners and Instrumentation
...a fully absorbable soft tissue anchor designed spe...s dynamic engagement into cancellous bone, its bro...de significant resistance to pullout in soft bone....ction provides the benefits of fixation strength c...
...ade; Ti Quick-T Fixation System is a single-step t...r secondary tissue fixation. This through tendon t...e Anchor combined with our pretied knot technology...e of PEEK-OPTIMA® LT3 polymer from Invibio. Th...
Medicine Products: